Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases
OwnerRajendra Sahai BHATNAGARinventor
Life of this patent
Estimating the term…
Abstract
Peptides and methods of use thereof, are disclosed for use in treating disorders caused by the novel coronavirus SARS-COV-2 or resulting from COVID-19 disease, such as systemic inflammation or pneumonia. The peptides modulate the activity of the transcription factor NF κB.
Claims26
A composition for treating COVID-19 comprising a therapeutically effective amount of a combination of:
- i) a first peptide of length six to twenty amino acids comprising the sequence YMAP[D]EV;
- and
- ii) a second peptide of length seven to twenty amino acids comprising the sequence ANVAENA.
4-6. (canceled)
(canceled)
A method of treating COVID-19 in a patient in need thereof, comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a peptide of length six to twenty amino acids comprising the sequence YMAP[D]EV.
A method of treating COVID-19 in a patient in need thereof, comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of a peptide of length seven to twenty amino acids comprising the sequence ANVAENA.
14-17. (canceled)
A method of treating COVID-19 in a patient in need thereof, comprising administering to a patient in need thereof a composition comprising a therapeutically effective amount of one or more peptides of four to twenty amino acid residues in length, wherein the peptide inhibits the activity of NF-kappa B.
19-20. (canceled)
24-40. (canceled)
A method of treating COVID-19 in a patient in need thereof, comprising administering to the patient an amount of one or more peptides effective to reduce expression of ACE2 receptor, TMPRSS2, or both ACE2 receptor and TMPRSS2;
- or
- administering to the patient an amount of one or more peptides effective to reduce expression of at least one of CHUK, NFKB1, or NFKB2;
- or
- administering to the patient an amount of one or more peptides effective to reduce expression of at least one of TNF, TNFRSF1A, or TNFRSF9;
- or
- administering to the patient an amount of one or more peptides effective to reduce expression of at least one of IL1A, IL1B, or IL6;
- or
- administering to the patient an amount of one or more peptides effective to reduce expression of at least one of CCL2, CCL5, or CXCL8.
43-46. (canceled)
51-57. (canceled)
Dependencies are inferred from the claim text.